论文部分内容阅读
用放射免疫分析法测定了１２例肝硬化患者异搏定治疗前后的血浆血栓烷Ｂ２（ＴｘＢ２）及６－酮－前列腺素Ｆ１α（６－酮－ＰＧＦ１α）浓度，同时设立１６例未用异搏定治疗的肝硬化患者（随机）为对照组。结果：治疗组治疗后与治疗前比较，ＴｘＢ２水平明显下降（Ｐ＜０．０１），６－酮－ＰＧＦ１α水平也有所升高，但无统计学意义（Ｐ＞０．０５）。提示异搏定对肝硬化患者的ＴｘＡ２－ＰＧＩ２失衡有调节作用，能减轻或改善肝硬化患者的高凝状态。有临床推广价值。
Radioimmunoassay was used to determine the levels of TXB2 and 6-keto-PGF1α before and after treatment with verapamil in 12 patients with cirrhosis. At the same time, 16 patients who did not use verapamil The patients with cirrhosis who were treated (random) were control group. Results: Compared with before treatment, the level of TxB2 in the treatment group was significantly decreased (P <0.01) and the level of 6-keto-PGF1α was also increased, but there was no statistical significance (P> 0.05). Tip verapamil in patients with liver cirrhosis TxA2-PGI2 imbalance in the regulation, can reduce or improve the hypercoagulability of patients with cirrhosis. A clinical promotion of value.